Ademi LLP probes Soleno's $2.9B deal with Neurocrine over shareholder fairness concerns

Ademi LLP is investigating Soleno Therapeutics' recent $2.9 billion transaction with Neurocrine, questioning whether the deal fairly serves public shareholders. The investigation focuses on possible breaches of fiduciary duty by Soleno's board, especially regarding restrictive terms that penalize competing bids. This scrutiny aims to protect shareholder rights amid the merger process. Investors interested in joining the probe can contact Ademi LLP for more information.